Artificial Intelligence With DEep Learning on COROnary Microvascular Disease
Launched by UNIVERSITY HOSPITAL, GRENOBLE · Oct 16, 2020
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how artificial intelligence (AI) can help doctors better understand and treat coronary microvascular disease, a condition that affects small blood vessels in the heart. The researchers believe that by using advanced AI techniques, specifically Deep Learning, they can analyze images from heart procedures more accurately to identify patients at risk for serious complications after a heart attack. The goal is to improve treatment strategies based on these insights, ultimately leading to better outcomes for patients.
To participate in this study, you need to be at least 18 years old and have undergone a specific heart procedure called coronary angioplasty for a heart attack between 2015 and 2018. Participants should also be covered by social security and agree to take part in the study. If you join, you can expect that your heart images will be analyzed using the latest AI technology, which could help improve how doctors assess heart health and plan treatments. This trial is currently looking for participants, and all genders are welcome to apply.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age over 18 years
- • Patients who have undergone coronary angioplasty revascularization at CHUGA for STEMI from 2015 to 2018 for which images are usable.
- • Patient affiliated with social security
- • Non-opposition to participation
- Exclusion Criteria:
- • Coronary artery image not usable
- • Patient under guardianship or deprived of liberty
About University Hospital, Grenoble
The University Hospital of Grenoble is a leading academic medical center dedicated to advancing healthcare through innovative clinical research and comprehensive patient care. As a prominent sponsor of clinical trials, the hospital leverages its expertise in various medical disciplines to facilitate cutting-edge studies that aim to improve treatment outcomes and enhance patient safety. With a strong commitment to collaboration, the University Hospital of Grenoble engages in partnerships with academic institutions, industry leaders, and regulatory bodies to drive scientific discovery and translate research findings into clinical practice. Its state-of-the-art facilities and multidisciplinary teams ensure rigorous adherence to ethical standards and regulatory guidelines, fostering an environment where groundbreaking research can thrive.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Grenoble, , France
Patients applied
Trial Officials
Gilles Barone-Rochette
Principal Investigator
University Hospital, Grenoble
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials